Proteomics

Dataset Information

0

Kinome profiling in HER2+ breast cancer patients in response to 7 days of HER2-targeting


ABSTRACT: Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in the tumor leading to resistance. HER2-directed therapy using clinically relevant drugs (trastuzumab with or without lapatinib or pertuzumab) in a 7-day clinical trial (ClinicalTrials.gov Identifier: NCT01875666, LCCC1214) designed to examine early pharmacodynamic response to antibody-based anti-HER2 therapy showed reduced FOXA1 transcription factor expression was coincident with decreased HER2 and HER3 levels, decreased proliferation gene signatures, and increased immune gene signatures. Patient samples from this trial, when sufficient material was available, were also subjected to kinase enrichment using multiplexed kinase inhibitor bead affinity chromatography and LC-MS/MS. Strongly responsive transcriptional responses observed in a subset of patients corresponded to decreased binding of CDK1 and DDR1 by our proteomic approach. Taken together, our results highlight the importance of the immune response to anti-HER2 antibodies and suggests that inhibiting FOXA1-mediated adaptive responses in combination with HER2 targeting is a potential therapeutic strategy.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast

DISEASE(S): Breast Cancer

SUBMITTER: Steven Angus  

LAB HEAD: Gary Johnson

PROVIDER: PXD021865 | Pride | 2021-04-09

REPOSITORIES: Pride

altmetric image

Publications


Inhibition of the HER2/ERBB2 receptor is a keystone to treating HER2-positive malignancies, particularly breast cancer, but a significant fraction of HER2-positive (HER2+) breast cancers recur or fail to respond. Anti-HER2 monoclonal antibodies, like trastuzumab or pertuzumab, and ATP active site inhibitors like lapatinib, commonly lack durability because of adaptive changes in the tumor leading to resistance. HER2+ cell line responses to inhibition with lapatinib were analyzed by RNAseq and ChI  ...[more]

Similar Datasets

2017-12-07 | PXD006139 | Pride
| E-GEOD-52138 | biostudies-arrayexpress
2020-11-19 | PXD019138 | Pride
2023-05-18 | PXD019005 | Pride
2024-01-26 | PXD040208 | Pride
| E-GEOD-61992 | biostudies-arrayexpress
2023-03-10 | PXD030571 | Pride
| E-GEOD-40267 | biostudies-arrayexpress
| E-GEOD-58886 | biostudies-arrayexpress
| E-GEOD-13825 | biostudies-arrayexpress